ESTROGEN REPLACEMENT THERAPY (ERT) IN HIGH-RISK CANCER-PATIENTS

Citation
Ka. Hutchinsonwilliams et Jn. Gutmann, ESTROGEN REPLACEMENT THERAPY (ERT) IN HIGH-RISK CANCER-PATIENTS, The Yale journal of biology & medicine, 64(6), 1991, pp. 607-626
Citations number
153
Language
INGLESE
art.tipo
Article
ISSN journal
0044-0086
Volume
64
Issue
6
Year of publication
1991
Pages
607 - 626
Database
ISI
SICI code
0044-0086(1991)64:6<607:ERT(IH>2.0.ZU;2-7
Abstract
Menopausal estrogens are now being prescribed not only for symptom rel ief, but also to prevent the long-term sequelae of estrogen deficiency , namely osteoporosis and atherosclerotic disease. The well-establishe d association between endometrial cancer and estrogen replacement ther apy (ERT) has become less of a clinical concern due to the recognition of the protective effect of progestogens in this setting. A small lit erature has emerged suggesting that extending ERT to the woman with a history of endometrial carcinoma imposes no increased risk of recurren ce and may improve survival. Candidates for ERT should be women with a better prognostic profile with reference to their cancer. The relatio nship between ERT and breast cancer remains a topic of intense debate and investigation. Overall, the current literature finds no significan t increase in risk among healthy women without a family history of bre ast cancer. There are no guidelines with reference to the woman with a history of breast cancer and the use of ERT. The most prudent approac h with this population is to consider alternative treatments until mor e is known.